1 INTRODUCTION
1.1 OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.3 RESEARCH METHODOLOGY
1.3.1 SECONDARY DATA
1.3.2 PRIMARY DATA
1.3.3 MARKET SIZE ESTIMATION
1.3.4 MARKET BREAKDOWN AND DATA TRIANGULATION
1.4 STAKEHOLDERS
1.5 CURRENCY
1.6 RESEARCH ASSUMPTIONS
1.7 LIMITATION
2 EXECUTIVE SUMMARY
3 MARKET OUTLOOK
3.1 INTRODUCTION
3.2 DROC MATRIX
3.3 MARKET CHALLENGES
3.4 MARKET SHARE ANALYSIS
3.5 COST STRUCTURE ANALYSIS
3.6 VALUE CHAIN ANALYSIS
3.7 COVID-19 IMPACT ANALYSES
4 INDUSTRY TRENDS
4.1 INTRODUCTION
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
4.3.1 DEGREE OF COMPETITION
4.3.2 BARGAINING POWER OF BUYERS
4.3.3 BARGAINING POWER OF SUPPLIERS
4.3.4 THREAT FROM SUBSTITUTES
4.3.5 THREAT FROM NEW ENTRANTS
5 CELL & GENE THERAPY TYPE ANALYSIS
5.1 INTRODUCTION
5.2 HISTORICAL MARKET TYPE ANALYSIS, 2017-2021
5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
5.4 Y-O-Y GROWTH TREND ANALYSIS
5.5 CELL THERAPY
5.5.1 STEM CELLS
5.5.2 T CELLS
5.5.3 DENDRITIC CELLS
5.5.4 NK CELLS
5.5.5 TUMOR CELLS
5.6 GENE THERAPY
6 CELL & GENE THERAPY MARKET THERAPEUTIC CLASS ANALYSIS
6.1 INTRODUCTION
6.2 HISTORICAL MARKET THERAPEUTIC CLASS ANALYSIS, 2017-2021
6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
6.4 Y-O-Y GROWTH TREND ANALYSIS
6.5 CARDIOVASCULAR DISEASE
6.6 CANCER
6.7 GENETIC DISORDER
6.8 RARE DISEASES
6.9 ONCOLOGY
6.10 HEMATOLOGY
6.11 OPHTHALMOLOGY
6.12 INFECTIOUS DISEASE
6.13 NEUROLOGICAL DISORDERS
7 CELL & GENE THERAPY MARKET DELIVERY METHOD ANALYSIS
7.1 INTRODUCTION
7.2 HISTORICAL MARKET DELIVERY METHOD ANALYSIS, 2017-2021
7.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
7.4 Y-O-Y GROWTH TREND ANALYSIS
7.5 IN VIVO
7.6 EX VIVO
8 CELL & GENE THERAPY MARKET END-USERS ANALYSIS
8.1 INTRODUCTION
8.2 HISTORICAL MARKET END-USERS ANALYSIS, 2017-2021
8.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
8.4 Y-O-Y GROWTH TREND ANALYSIS
8.5 IN HOUSE
8.6 OUTSOURCED
9 CELL & GENE THERAPY MARKET APPLICATION ANALYSIS
9.1 INTRODUCTION
9.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2017-2021
9.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
9.4 Y-O-Y GROWTH TREND ANALYSIS
9.5 HOSPITALS
9.6 CANCER CARE CENTERS
9.7 WOUND CARE CENTERS
9.8 OTHERS
10 GLOBAL CELL & GENE THERAPY REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
10.2.3 Y-O-Y GROWTH TREND ANALYSIS
10.2.3.1 U.S.
10.2.3.2 Canada
10.2.3.3 Mexico
10.3 ASIA-PACIFIC
10.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.3.2 Y-O-Y GROWTH TREND ANALYSIS
10.3.2.1 China
10.3.2.2 Japan
10.3.2.3 Korea
10.3.2.4 India
10.3.2.5 Southeast Asia
10.4 MIDDLE EAST AND AFRICA
10.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
10.4.3 Y-O-Y GROWTH TREND ANALYSIS
10.4.3.1 Saudi Arabia
10.4.3.2 UAE
10.4.3.3 Egypt
10.4.3.4 Nigeria
10.4.3.5 South Africa
10.5 EUROPE
10.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
10.5.3 Y-O-Y GROWTH TREND ANALYSIS
10.5.3.1 Germany
10.5.3.2 France
10.5.3.3 UK
10.5.3.4 Russia
10.5.3.5 Italy
10.6 SOUTH AMERICA
10.6.1 SOUTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
10.6.3 Y-O-Y GROWTH TREND ANALYSIS
10.6.3.1 Brazil
10.6.3.2 Argentina
10.6.3.3 Columbia
11 COUNTRY LEVEL ANALYSIS
11.1 UNITED STATES
11.2 CANADA
11.3 MEXICO
11.4 CHINA
11.5 JAPAN
11.6 INDIA
11.7 KOREA
11.8 SAUDI AREBIA
11.9 UAE
11.10 EGYPT
11.11 NIGERIA
11.12 SOUTH AFRICA
11.13 GERMANY
11.14 FRANCE
11.15 UK
11.16 RUSSIA
11.17 ITALY
11.18 BRAZIL
11.19 ARGENTINA
11.20 COLUMBIA
12 MARKET PLAYERS
12.1 ALNYLAM PHARMACEUTICALS INC.
12.1.1 BUSINESS OVERVIEW:
12.1.2 PRODUCT PORTFOLIO
12.1.3 RECENT DEVELOPMENTS
12.1.4 SWOT ANALYSIS:
12.2 AMGEN INC.
12.3 BIOGEN INC.
12.4 CORESTEM INC.
12.5 DENDREON PHARMACEUTICALS LLC.
12.6 HELIXMITH CO. LTD.
12.7 JCR PHARMACEUTICALS CO. LTD.
12.8 KOLON TISSUEGENE INC.
12.9 NOVARTIS AG
12.10 PFIZER INC.
12.11 BLUEBIRD BIO INC.
12.12 BRISTOL-MYERS SQUIBB CO.
12.13 GILEAD SCIENCES INC.
12.14 ORCHARD THERAPEUTICS PLC.
12.15 PHARMICELL CO. LTD.
12.16 SIBIONO GENETECH CO. LTD.
12.17 VERICEL CORP.
12.18 SMITH NEPHEW (OSIRIS THERAPEUTIC)
12.19 ORGANOGENESIS
12.20 ROCHE (SPARK THERAPEUTICS)
13 ABOUT US

TABLE 1 CELL & GENE THERAPY REGIONAL HISTORICAL MARKET ANALYSIS, 2017–2021 (USD MILLION)
TABLE 2 GLOBAL CELL & GENE THERAPY MARKET, 2022–2031, (USD MILLION)
TABLE 3 CELL & GENE THERAPY CURRENT AND FUTURE REGIONAL ANALYSIS, 2022–2031 (USD MILLION)
TABLE 4 GLOBAL CELL & GENE THERAPY HISTORICAL MARKET TYPE ANALYSIS, 2017-2021, (USD MILLION)
TABLE 5 CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 6 GLOBAL CELL & GENE THERAPY HISTORICAL MARKET THERAPEUTIC CLASS ANALYSIS, 2017-2021, (USD MILLION)
TABLE 7 CELL & GENE THERAPY CURRENT AND FUTURE THERAPEUTIC CLASS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 8 GLOBAL CELL & GENE THERAPY HISTORICAL MARKET DELIVERY METHOD ANALYSIS, 2017-2021, (USD MILLION)
TABLE 9 CELL & GENE THERAPY CURRENT AND FUTURE DELIVERY METHOD ANALYSIS, 2022–2031 (USD MILLION)
TABLE 10 GLOBAL CELL & GENE THERAPY HISTORICAL MARKET END-USERS ANALYSIS, 2017-2021, (USD MILLION)
TABLE 11 CELL & GENE THERAPY CURRENT AND FUTURE END-USERS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 12 GLOBAL CELL & GENE THERAPY HISTORICAL MARKET APPLICATION ANALYSIS, 2017-2021, (USD MILLION)
TABLE 13 CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 14 NORTH AMERICA CELL & GENE THERAPY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 15 NORTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 16 NORTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE THERAPEUTIC CLASS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 17 NORTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE DELIVERY METHOD ANALYSIS, 2022–2031 (USD MILLION)
TABLE 18 NORTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE END-USERS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 19 NORTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 20 U.S. CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2017–2023
TABLE 21 U.S. CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 22 U.S. CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 23 CANADA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 24 CANADA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 25 MEXICO CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 26 MEXICO CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 27 APAC CELL & GENE THERAPY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 28 ASIA-PACIFIC CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 29 ASIA-PACIFIC CELL & GENE THERAPY CURRENT AND FUTURE THERAPEUTIC CLASS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 30 ASIA-PACIFIC CELL & GENE THERAPY CURRENT AND FUTURE DELIVERY METHOD ANALYSIS, 2022–2031 (USD MILLION)
TABLE 31 ASIA-PACIFIC CELL & GENE THERAPY CURRENT AND FUTURE END-USERS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 32 ASIA-PACIFIC CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 33 CHINA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 34 CHINA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 35 JAPAN CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 36 JAPAN CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 37 KOREA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 38 KOREA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 39 INDIA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 40 INDIA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 41 SOUTHEAST ASIA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 42 SOUTHEAST ASIA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA CELL & GENE THERAPY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA CELL & GENE THERAPY CURRENT AND FUTURE THERAPEUTIC CLASS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA CELL & GENE THERAPY CURRENT AND FUTURE DELIVERY METHOD ANALYSIS, 2022–2031 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA CELL & GENE THERAPY CURRENT AND FUTURE END-USERS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 49 SAUDI ARABIA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 50 SAUDI ARABIA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 51 UAE CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 52 UAE CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 53 EGYPT CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 54 EGYPT CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 55 NIGERIA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 56 NIGERIA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 57 SOUTH AFRICA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 58 SOUTH AFRICA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 59 EUROPE CELL & GENE THERAPY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 60 EUROPE CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 61 EUROPE CELL & GENE THERAPY CURRENT AND FUTURE THERAPEUTIC CLASS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 62 EUROPE CELL & GENE THERAPY CURRENT AND FUTURE DELIVERY METHOD ANALYSIS, 2022–2031 (USD MILLION)
TABLE 63 EUROPE CELL & GENE THERAPY CURRENT AND FUTURE END-USERS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 64 EUROPE CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 65 GERMANY CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 66 GERMANY CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 67 FRANCE CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 68 FRANCE CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 69 UK CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 70 UK CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 71 RUSSIA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 72 RUSSIA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 73 ITALY CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 74 ITALY CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 75 SOUTH AMERICA CELL & GENE THERAPY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 76 SOUTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 77 SOUTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE THERAPEUTIC CLASS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 78 SOUTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE DELIVERY METHOD ANALYSIS, 2022–2031 (USD MILLION)
TABLE 79 TABLE 82 SOUTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE END-USERS ANALYSIS, 2022–2031 (USD MILLION)
TABLE 80 SOUTH AMERICA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 81 BRAZIL CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 82 BRAZIL CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 83 ARGENTINA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 84 ARGENTINA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 85 COLUMBIA CELL & GENE THERAPY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 86 COLUMBIA CELL & GENE THERAPY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)